GlassScriptPhysician profile
Senthilkumar Sankararaman
NPI 1033358858
$2,664.10
in general payments reported to CMS, 2019-2025
13 companies · $251 in 2025
The $251 reported for 2025 was more than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.96 · 2020: $11.99 · 2021: $155 · 2022: $118 · 2023: $1,906 · 2024: $189 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,400 · Food and Beverage: $946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,400.00 |
| Food and Beverage | $945.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $1,601.70 | 2023 | |
| Alcresta Therapeutics, INC. | $238.98 | 2024-2025 | Relizorb |
| Chiesi USA, INC. | $160.96 | 2021-2022 | |
| Genzyme Corporation | $153.45 | 2023-2024 | |
| Mylan Specialty L.P. | $122.17 | 2023 | Tobi Podhaler |
| Aimmune Therapeutics, INC. | $100.49 | 2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $77.88 | 2023-2024 | Dupixent |
| Abbvie INC. | $61.61 | 2021-2023 | Rinvoq |
| Qol Medical, LLC | $46.75 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.32 | 2021 | |
| Alexion Pharmaceuticals, INC. | $32.96 | 2019 | |
| Digestive Care, INC. | $30.83 | 2025 | Pertzye |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Senthilkumar Sankararaman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.